Most people start a GLP-1 medication with one goal in mind: Weight loss.
The number on the scale often becomes the primary measure of success. But emerging research suggests these medications may be influencing much more than body weight alone.
Researchers are beginning to uncover potential benefits related to metabolic health, inflammation, insulin sensitivity, and even hormone levels. While more research is needed, these findings reinforce an important reality: the body’s systems are interconnected.
Why This Matters
Low testosterone is common among men with obesity. Excess body fat can increase the conversion of testosterone to estrogen through the aromatase enzyme, which may disrupt normal hormone production. Obesity is also associated with chronic inflammation and insulin resistance, both of which can negatively affect hormonal balance.
As metabolic health improves, hormone levels often improve as well. Better insulin sensitivity, reduced inflammation, improved sleep quality, and weight loss can all contribute to healthier testosterone levels.
This means that improvements in body composition, energy, recovery, glucose regulation, and hormone production may occur together rather than independently.
What the Research Found
Researchers at SSM Health Saint Louis University Hospital followed 110 adult men with obesity or type 2 diabetes who were treated with GLP-1 medications, including semaglutide, dulaglutide, and tirzepatide. Participants were monitored for 18 months, with researchers evaluating changes in both total and free testosterone levels.
The results were noteworthy.
The percentage of men with normal total and free testosterone levels increased from 53% at baseline to 77% during treatment. According to lead investigator Dr. Shellsea Portillo Canales, these findings provide early evidence that commonly prescribed anti-obesity medications may help reverse low testosterone levels in some men with obesity.
Researchers are still determining whether these hormonal improvements are driven primarily by weight loss itself or whether GLP-1 medications may have additional direct effects on metabolic and endocrine function.
It is important to note that these findings have not yet undergone peer review.
Looking Beyond the Scale
Weight loss is only one measure of progress.
If you’re utilizing a GLP-1 medication as part of your wellness journey, consider tracking additional markers of health, including:
✅ Blood glucose and HbA1c
✅ Fasting insulin levels
✅ Lipid profile
✅ Inflammatory markers
✅ Hormone levels when clinically appropriate
✅ Body composition changes
✅ Energy, sleep quality, and recovery
Comprehensive laboratory testing before starting treatment and at regular intervals throughout the first year can provide valuable insight into how your body is responding. Many healthcare providers recommend periodic monitoring to evaluate progress, identify potential concerns, and guide individualized treatment decisions.
The Bigger Picture
GLP-1 medications are powerful tools for improving metabolic health and supporting sustainable weight loss. While the scale often receives the most attention, improvements in hormonal health, insulin sensitivity, inflammation, and overall well-being may also be occurring.
The goal isn’t simply to lose weight—it’s to improve health.
That’s why successful long-term results often include more than medication alone. Proper nutrition, regular physical activity, healthy lifestyle habits, and appropriate clinical oversight all play an important role in maximizing outcomes and supporting lasting success.
References
Endocrine Society. (2025). Anti-obesity medications can normalize testosterone levels in men (Press Release).
Mammoser, G. (2025). GLP-1 drugs may improve low testosterone. Healthline.
Burnett-Bowie, S. A. M., et al. (2020). Aromatase inhibitors plus weight loss improves the hormonal profile of obese hypogonadal men without causing major side effects. Frontiers in Endocrinology, 11, 277.
Altered Expression of Aromatase and Estrogen Receptors in Adipose Tissue From Men With Obesity or Type 2 Diabetes. (2025). The Journal of Clinical Endocrinology & Metabolism, 110(10), e3410-e3422.
This information is intended for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding diagnosis, treatment, or changes to your healthcare plan.
